Today it was reported that a Director at ANI Pharmaceuticals Inc (ANIP), Robert E. Brown, exercised options to buy 2,209 ANIP shares at $20.43 a share, for a total transaction value of $45.14K.
Following Robert E. Brown’s last ANIP Buy transaction on November 16, 2016, the stock climbed by 12.7%. This recent transaction increases Robert E. Brown’s holding in the company by 11.51% to a total of $1.59 million.
See today’s analyst top recommended stocks >>
Based on ANI Pharmaceuticals Inc’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $52.89 million and quarterly net profit of $440K. In comparison, last year the company earned revenue of $46.48 million and had a net profit of $2.24 million. ANIP’s market cap is $846.9M and the company has a P/E ratio of 61.42. Currently, ANI Pharmaceuticals Inc has an average volume of 125.3K.
Starting in June 2018, ANIP received 17 Buy ratings in a row. Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $84.00, reflecting a 20.1% upside. Three different firms, including Raymond James and Canaccord Genuity, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $2.62M worth of ANIP shares and purchased $218.4K worth of ANIP shares. The insider sentiment on ANI Pharmaceuticals Inc has been negative according to 35 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products.
